An overview of lipid abnormalities in patients with inflammatory bowel disease

Annals of Gastroenterology

Volumn 24, Issue 3, 2011, Pages 181-187

  Agouridis, Aris P ^a   Elisaf, Moses ^a   Milionis, Haralampos J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Crohn's disease; High density lipoprotein cholesterol; Inflammatory bowel disease; Low density lipoprotein cholesterol; Total cholesterol; Triglycerides; Ulcerative colitis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METRONIDAZOLE; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL;

BODY MASS; CHOLESTEROL BLOOD LEVEL; CROHN DISEASE; CYTOKINE PRODUCTION; DIETARY INTAKE; DISEASE ASSOCIATION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENTERITIS; HIGH RISK PATIENT; HUMAN; INTESTINE RESECTION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; PARENTERAL NUTRITION; PROCTOCOLECTOMY; REVIEW; RISK FACTOR; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS;

EID: 79961214882     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99:1371-1385
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429
3. Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis 2005;11:304-313
4. Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J Gastroenterol 2008;14:338-347
5. Ishihara S, Aziz MM, Yuki T, Kazumori H, Kinoshita Y. Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol 2009;44:1097-1108
6. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397
7. Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005;22:839-846
8. Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol 2005;100:886-895
9. Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm Bowel Dis 2006;12:53-56
10. Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology 2010;61:198-204
11. Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol 2007;102:1050-1055
12. Visschers RG, Olde Damink SW, Schreurs M, Winkens B, Soeters PB, van Gemert WG. Development of hypertriglyceridemia in patients with enterocutaneous fistulas. Clin Nutr 2009;28:313-317
13. Crook MA, Velauthar U, Moran L, Griffiths W. Hypocholeste rolaemia in a hospital population. Ann Clin Biochem 1999;36 (Pt 5):613-616
14. Long MD, Crandall WV, Leibowitz IH, et al. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease. Inflamm Bowel Dis 2010. 2010 Dec 17. [Epub ahead of print]
15. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol 2010;4:478-482
16. Hrabovsky V, Zadak Z, Blaha V, et al. Cholesterol metabolism in active Crohn's disease. Wien Klin Wochenschr 2009;121:270-275
17. Romanato G, Scarpa M, Angriman I, et al. Plasma lipids and inflammation in active inflammatory bowel diseases. Aliment Pharmacol Ther 2009;29:298-307
18. Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism 2006;55:980-988
19. Koutroubakis IE, Malliaraki N, Vardas E, et al. Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis? Eur J Gastroenterol Hepatol 2001;13:1415-1419
20. Koutroubakis IE, Dilaveraki E, Vlachonikolis IG, et al. Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. Dig Dis Sci 2000;45:2347-2351
21. Kawabata S, Katagiri S, Negoro H, et al. Elevated serum lipoprotein (a) levels associated with ulcerative colitis in a young Japanese Annals of Gastroenterology 24 patient. Intern Med 1997;36:389-391
22. Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000;71:807-815
23. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. J Intern Med 1998;243:339-347
24. Stadnicki A, Bojko B, Myczkowska K, Witalinska-Labuzek J. [Selected risk factors of thrombotic complications in patients with ulcerative colitis]. Wiad Lek 2003;56:341-347
25. Aozaki S. Decreased membrane fluidity in erythrocytes from patients with Crohn's disease. Gastroenterol Jpn 1989;24:246-254
26. Parkes M, Jewell DP. Review article: the management of severe Crohn's disease. Aliment Pharmacol Ther 2001;15:563-573
27. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120-127
28. Romanato G, Scarpa M, Ruffolo C, et al. Lipid and phospholipid profile after bowel resection for Crohn's disease. Int J Colorectal Dis 2008;23:931-938
29. Scarpa M, Romanato G, Manzato E, et al. Restorative proctocolectomy for ulcerative colitis: impact on lipid metabolism and adipose tissue and serum fatty acids. J Gastrointest Surg 2008;12:279-287
30. Lundin EA, Zhang JX, Lairon D, et al. Effects of meal frequency and high-fibre rye-bread diet on glucose and lipid metabolism and ileal excretion of energy and sterols in ileostomy subjects. Eur J Clin Nutr 2004;58:1410-1419
31. Kuisma J, Nuutinen H, Luukkonen P, Jarvinen H, Kahri A, Farkkila M. Long term metabolic consequences of ileal pouch-anal anastomosis for ulcerative colitis. Am J Gastroenterol 2001;96:3110- 3116
32. Hakala K, Vuoristo M, Luukkonen P, Jarvinen HJ, Miettinen TA. Impaired absorption of cholesterol and bile acids in patients with an ileoanal anastomosis. Gut 1997;41:771-777
33. Akerlund JE, Bjorkhem I, Angelin B, Liljeqvist L, Einarsson K. Apparent selective bile acid malabsorption as a consequence of ileal exclusion: effects on bile acid, cholesterol, and lipoprotein metabolism. Gut 1994;35:1116-1120
34. Akerlund JE, Reihner E, Angelin B, et al. Hepatic metabolism of cholesterol in Crohn's disease. Effect of partial resection of ileum. Gastroenterology 1991;100:1046-1053
35. Kawakami Y, Okada H, Murakami Y, et al. Dietary intake, neutrophil fatty acid profile, serum antioxidant vitamins and oxygen radical absorbance capacity in patients with ulcerative colitis. J Nutr Sci Vitaminol (Tokyo) 2007;53:153-159
36. Tanaka M, Iwao Y, Sasaki S, et al. Moderate dietary temperance effectively prevents relapse of Crohn disease: a prospective study of patients in remission. Gastroenterol Nurs 2007;30:202-210
37. Bjorck S, Bosaeus I, Ek E, et al. Food induced stimulation of the antisecretory factor can improve symptoms in human inflammatory bowel disease: a study of a concept. Gut 2000;46:824- 829
38. Mingrone G, Capristo E, Greco AV, et al. Elevated diet-induced thermogenesis and lipid oxidation rate in Crohn disease. Am J Clin Nutr 1999;69:325-330
39. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009;54:585-594
40. Gazi I, Liberopoulos EN, Saougos VG, Elisaf M. Beneficial effects of omega-3 fatty acids: the current evidence. Hellenic J Cardiol 2006;47:223-231
41. Kuroki F, Iida M, Matsumoto T, Aoyagi K, Kanamoto K, Fujishima M. Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease. Dig Dis Sci 1997;42:1137-1141
42. Endres S, Lorenz R, Loeschke K. Lipid treatment of inflammatory bowel disease. Curr Opin Clin Nutr Metab Care 1999;2:117-120
43. Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009:CD006320
44. John S, Luben R, Shrestha SS, Welch A, Khaw KT, Hart AR. Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur J Gastroenterol Hepatol 2010;22:602-606
45. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299:1690-1697
46. Prinz V, Endres M. The acute (cerebro) vascular effects of statins. Anesth Analg 2009;109:572-584
47. Watson KE. The JUPITER trial: How will it change clinical practice? Rev Cardiovasc Med 2009;10:91-96
48. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
50. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
51. Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821
52. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-651
53. Samadder NJ, Mukherjee B, Huang SC, et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 2010. 2011;117:1640-1648
54. Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 2009;4:e5263
55. Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol 2008;155:1085-1092
56. Grip O, Janciauskiene S, Lindgren S. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis 2004;10:193-200
57. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958-961
58. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-2446
59. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1495-1498
60. Kiortsis DN, Mavridis AK, Filippatos TD, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2006;33:921-923
61. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005;64:765-766
62. Derdemezis CS, Filippatos TD, Voulgari PV, Tselepis AD, Drosos AA, Kiortsis DN. Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment. Clin Exp Rheumatol 2010;28:880-883
63. Parmentier-Decrucq E, Duhamel A, Ernst O, et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis 2009;15:1476-1484
64. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009;21:283-288
65. Davis JL, Schultz TA, Mosley CA. Metronidazole lowers serum lipids. Ann Intern Med 1983;99:43-44
66. von Bergmann K, Streicher U, Leiss O, Jensen C, Gugler R. Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klin Wochenschr 1985;63:279-281
67. Weinberg RB, Singh KK. Short-term parenteral nutrition with glucose and Intralipid: effects on serum lipids and lipoproteins. Am J Clin Nutr 1989;49:794-798
68. Richelle M, Rubin M, Kulapongse S, Deckelbaum RJ, Elwyn DH, Carpentier YA. Plasma lipoprotein pattern during long-term home parenteral nutrition with two lipid emulsions. JPEN J Parenter Enteral Nutr 1993;17:432-437
69. Giovannini I, Boldrini G, Chiarla C, Giuliante F, Vellone M, Nuzzo G. Pathophysiologic correlates of hypocholesterolemia in critically ill surgical patients. Intensive Care Med 1999;25:748-751
70. Fraunberger P, Nagel D, Walli AK, Seidel D. Serum cholesterol and mortality in patients with multiple organ failure. Crit Care Med 2000;28:3574-3575